MS patients newly enrolled in TOUCH prescribing program

Prescreen and consent

Baseline survey (n = 1,275)

Completed baseline survey (n = 1,275)

6th infusion* follow-up survey (n = 452)

Completed at least 1st follow-up survey (n = 786)

3rd infusion* follow-up survey (n = 786)

No longer on natalizumab (n = 171)

Lost to follow-up (n = 157)

Never started natalizumab (n = 86)

Did not complete any of the follow-up surveys (n = 489)

No longer on natalizumab (n = 115)

No longer eligible – had 4th infusion (n = 62)

Lost to follow-up (n = 226)

*One natalizumab infusion every 4 weeks